The Fluidigm 48.48 Dynamic Array from Fluidigm Europe provides a highly efficient solution for single cell gene expression quantification studies using off-the-shelf TaqMan® PCR assays and reagents.
Historically, single-cell gene expression experiments have been difficult and expensive to perform. Fluidigm has introduced a new single-cell gene expression technique that, when used with the BioMark™ System, produces inexpensive, easily reproduced, gene expression results from single cell samples.
The key to this technological advance is the matrix of channels, chambers, and valves in Fluidigm's unique 48.48 Dynamic Array that do the work of assembling assays. Using the product - scientists can enjoy the same qPCR data quality and experiment flexibility that they are currently receiving from a 384-well system while increasing throughput 24X.
To run an experiment - 48 samples and 48 assays are loaded into the inlets of the Dynamic Array input frame and pressure loaded into 2,304 reaction chambers. Using this simple approach scientists are able to test 48 genes against 48 samples in a single run.
The savings in time and effort add up rapidly. For example, a 2,000-sample study that could be completed with 4,032 pipetting steps using the Fluidigm 48.48 Dynamic Array would require 192,000 steps to complete the same study using microplates. With dynamic arrays, genetic researchers can advance their research much more easily and affordably, and they can do so while using gold-standard TaqMan® assays.
Fluidigm develops, manufactures and markets proprietary IFC systems that significantly improve productivity in life science research. Fluidigm's IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These "integrated circuits for biology" are made possible by miniaturizing and integrating liquid handling components on a single microfabricated device. Fluidigm's IFC systems, consisting of instrumentation, software and single-use IFCs, increase throughput, decrease costs and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the Food and Drug Administration for use as a diagnostic and are only available for research use.